BIOT:SW:SW-L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF (CHF)

ETF | Others |

Last Closing

USD 8.534

Change

0.00 (0.00)%

Market Cap

N/A

Volume

102.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XLDX:SW Xtrackers LevDAX Daily Swap UC..

-1.52 (-0.83%)

USD 411,075.38B
XNIF:SW Xtrackers Nifty 50 Swap UCITS ..

+1.15 (+0.49%)

USD 292,109.69B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+13.50 (+0.28%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+9.20 (+0.61%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-8.50 (-0.41%)

USD 134,034.85B
SX7EEX:SW iShares EURO STOXX Banks 30-15..

N/A

USD 6,289.31B
TDXPEX:SW iShares TecDAX® UCITS ETF (DE..

-0.11 (-0.34%)

USD 5,933.97B
SMIEX:SW iShares SLI UCITS ETF (DE)

+1.50 (+1.11%)

USD 5,933.96B
DJSXE:SW iShares Core EURO STOXX 50 UCI..

N/A

USD 5,933.96B

ETFs Containing BIOT:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.09% 9% A- 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.09% 8% B- 12% F
Trailing 12 Months  
Capital Gain -16.17% 2% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.17% 2% F 7% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -4.98% 5% F 8% B-
Dividend Return -4.98% 5% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.50% 38% F 46% F
Risk Adjusted Return -58.62% 4% F 5% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CHF)

Quarterly Financials (CHF)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.